<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">r-n-j</journal-id><journal-title-group><journal-title xml:lang="ru">Российский неврологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian neurological journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2658-7947</issn><issn pub-type="epub">2686-7192</issn><publisher><publisher-name>МИА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30629/2658-7947-2019-24-6-29-38</article-id><article-id custom-type="elpub" pub-id-type="custom">r-n-j-44</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ И НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL RESEARCH AND SURVEILLANCE</subject></subj-group></article-categories><title-group><article-title>Амилоидный ангиит и прогрессирующий корковый поверхностный сидероз как агрессивные фенотипы церебральной амилоидной ангиопатии: принципы рационального ведения пациентов</article-title><trans-title-group xml:lang="en"><trans-title>Amyloid angiitis and progressive cortical superficial siderosis as aggressive phenotypes of cerebral amyloid angiopathy: principles of rational management</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6061-8118</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кулеш</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulesh</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кулеш Алексей Александрович.</p><p>Пермь.</p></bio><bio xml:lang="en"><p>Kulesh Alexey A.</p><p>Perm.</p></bio><email xlink:type="simple">aleksey.kulesh@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8922-5764</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горст</surname><given-names>Н. Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Gorst</surname><given-names>N. Kh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пермь.</p></bio><bio xml:lang="en"><p>Perm.</p></bio><email xlink:type="simple">GorstHope@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzina</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пермь.</p></bio><bio xml:lang="en"><p>Perm.</p></bio><email xlink:type="simple">evgenij.83kuzin@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8523-2692</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дробаха</surname><given-names>В. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Drobakha</surname><given-names>V. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пермь.</p></bio><bio xml:lang="en"><p>Perm.</p></bio><email xlink:type="simple">drobakha.v@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6310-9316</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шестаков</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shestakov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пермь.</p></bio><bio xml:lang="en"><p>Perm.</p></bio><email xlink:type="simple">shvnerv@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7536-2060</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каракулова</surname><given-names>Ю. B.</given-names></name><name name-style="western" xml:lang="en"><surname>Karakulova</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пермь.</p></bio><bio xml:lang="en"><p>Perm.</p></bio><email xlink:type="simple">julia.karakulova@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Пермский государственный медицинский университет им. академика Е.А. Вагнера Минздрава России; Городская клиническая больница №4</institution><country>Россия</country></aff><aff xml:lang="en"><institution>E.A. Vagner Perm State Medical University; City Clinical Hospital №4</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Пермский государственный медицинский университет им. академика Е.А. Вагнера Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>E.A. Vagner Perm State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Пермская центральная районная больница</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Perm central district hospital</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>28</day><month>01</month><year>2020</year></pub-date><volume>24</volume><issue>6</issue><fpage>29</fpage><lpage>38</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кулеш А.А., Горст Н.Х., Кузина Е.В., Дробаха В.Е., Шестаков В.В., Каракулова Ю.B., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Кулеш А.А., Горст Н.Х., Кузина Е.В., Дробаха В.Е., Шестаков В.В., Каракулова Ю.B.</copyright-holder><copyright-holder xml:lang="en">Kulesh A.A., Gorst N.K., Kuzina N.V., Drobakha V.E., Shestakov V.V., Karakulova Y.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.r-n-j.com/jour/article/view/44">https://www.r-n-j.com/jour/article/view/44</self-uri><abstract><p>Церебральная  амилоидная  ангиопатия  (ЦАА) — распространенное  в старшей возрастной  группе заболевание, обладающее высокой клинической и визуализационной  гетерогенностью.  Представлены обзор литературы и два клинических случая, отражающих различные фенотипы ЦАА, — амилоидный ангиит (ЦАА, ассоциированная  с воспалением)  и «геморрагический  фенотип» (ЦАА, ассоциированная  с внутримозговым кровоизлиянием и прогрессирующим корковым поверхностным сидерозом). В каждом случае применительно к клинико-нейровизуализационной  картине рассмотрены направления спорных векторов вторичной профилактики и терапии ЦАА: антитромботической, антигипертензивной и гиполипидемической. Обсуждаются вопросы эпидемиологии, патогенеза, диагностики и лечения ЦАА.</p></abstract><trans-abstract xml:lang="en"><p>Cerebral amyloid angiopathy (CAA) is a common disease in the older age group with high clinical and neurovisual heterogeneity. A literature review and two clinical cases reflecting different phenotypes of CAA are presented — amyloid angiitis (CAA-related inflammation) and “hemorrhagic phenotype” (CAA associated with intracerebral hemorrhage and progressive cortical superficial siderosis). In each case, in relation to the clinical and neuroimaging picture, the directions of the disputed vectors of secondary prevention and therapy of CAA are considered: antithrombotic, antihypertensive and lipid-lowering therapy. The issues of epidemiology, pathogenesis, diagnosis and treatment of CAA are discussed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>церебральная амилоидная ангиопатия</kwd><kwd>ассоциированная с воспалением</kwd><kwd>церебральные микрокровоизлияния</kwd><kwd>корковый поверхностный сидероз</kwd><kwd>антитромботическая терапия</kwd><kwd>гиполипидемическая терапия</kwd><kwd>антигипертензивная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cerebral amyloid angiopathy-related inflammation</kwd><kwd>cerebral microbleeds</kwd><kwd>cortical superficial siderosis</kwd><kwd>antithrombotic therapy</kwd><kwd>lipid-lowering therapy</kwd><kwd>antihypertensive therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Attems J, Lauda F, Jellinger KA. Unexpectedly low prevalence of intracerebral hemorrhages in sporadic cerebral amyloid angiopathy: an autopsy study. J Neurol. 2008;255:70–76.</mixed-citation><mixed-citation xml:lang="en">Attems J, Lauda F, Jellinger KA. Unexpectedly low prevalence of intracerebral hemorrhages in sporadic cerebral amyloid angiopathy: an autopsy study. J Neurol. 2008;255:70–76.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Charidimou A, Boulouis G, Gurol ME et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain. 2017;140(7):1829–1850.</mixed-citation><mixed-citation xml:lang="en">Charidimou A, Boulouis G, Gurol ME et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain. 2017;140(7):1829–1850.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Keable A, Fenna K, Yuen HM, Johnston DA, Smyth NR, Smith C. et al. Deposition of amyloid beta in the walls of human leptomen-ingeal arteries in relation to perivascular drainage pathways in cere-bral amyloid angiopathy. Biochim Biophys Acta. 2016;1862:1037–464.</mixed-citation><mixed-citation xml:lang="en">Keable  A,  Fenna  K,  Yuen  HM,  Johnston  DA,  Smyth  NR, Smith C. et al. Deposition of amyloid beta in the walls of human leptomen-ingeal arteries in relation to perivascular drainage pathways in cere-bral amyloid angiopathy. Biochim Biophys Acta. 2016;1862:1037–464.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38:254–259. doi: 10.1002/ana.410380219</mixed-citation><mixed-citation xml:lang="en">Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38:254–259. doi: 10.1002/ana.410380219</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Knudsen K, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001Feb;27;56(4):537–9. doi: 10.1212/wnl.56.4.537</mixed-citation><mixed-citation xml:lang="en">Knudsen K, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001Feb;27;56(4):537–9. doi: 10.1212/wnl.56.4.537</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Greenberg SM, Charidimou A. Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the Boston Criteria. Stroke. 2018;49(2):491–497.</mixed-citation><mixed-citation xml:lang="en">Greenberg  SM,  Charidimou A.  Diagnosis  of  Cerebral Amyloid  Angiopathy:  Evolution  of  the  Boston  Criteria.  Stroke. 2018;49(2):491–497.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Кулеш А.А., Дробаха В.Е., Шестаков В.В. Геморрагические проявления церебральной амилоидной ангиопатии — от патогенеза к клиническому значению. Неврология, нейропсихиатрия, психосоматика. 2018;10(3):4–11.</mixed-citation><mixed-citation xml:lang="en">Kulesh AA, Drobakha  VE,  Shestakov  VV.  Hemorrhagic  manifestations of  cerebral  amyloid  angiopathy:  from  pathogenesis  to  clinical  significance. Neurology,  neuropsychiatry,  psychosomatics. 2018;10(3):4–11.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Greenberg SM, Salman RA, Biessels GJ et al. Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurol. 2014;13:419–28.</mixed-citation><mixed-citation xml:lang="en">Greenberg SM, Salman RA, Biessels GJ et al. Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurol. 2014;13:419–28.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Corovic A, Kelly S, Markus HS. Cerebral amyloid angiopathy associated with inflammation: A systematic review of clinical and imaging features and outcome. Int J Stroke. 2018Apr;13(3):257–267. doi: 10.1177/1747493017741569</mixed-citation><mixed-citation xml:lang="en">Corovic A, Kelly S, Markus HS. Cerebral amyloid angiopathy associated with inflammation: A systematic review of clinical and imaging features and outcome. Int J Stroke. 2018Apr;13(3):257–267. doi: 10.1177/1747493017741569</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chung KK, Anderson NE, Hutchinson D, Synek B, Barber PA. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry. 2011Jan;82(1):20–6. doi: 10.1136/jnnp.2009.204180</mixed-citation><mixed-citation xml:lang="en">Chung KK, Anderson NE, Hutchinson D, Synek B, Barber PA. Cerebral   amyloid   angiopathy   related   inflammation:   three case  reports  and  a  review.  J  Neurol  Neurosurg  Psychiatry. 2011Jan;82(1):20–6. doi: 10.1136/jnnp.2009.204180</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wardlaw JM, Smith EE, Biessels GJ. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013Aug;12(8):822–38. doi: 10.1016/S1474-4422(13)70124–8.</mixed-citation><mixed-citation xml:lang="en">Wardlaw JM, Smith EE, Biessels GJ. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013Aug;12(8):822–38. doi: 10.1016/S1474-4422(13)70124–8.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Renard D, Tatu L, Collombier L, Wacongne A, Ayrignac X, Charif M, et al. Cerebral Amyloid Angiopathy and Cerebral Amyloid Angiopathy-Related Inflammation: Comparison of Hemorrhagic and DWI MRI Features. J Alzheimers Dis. 2018;64(4):1113–1121. doi: 10.3233/JAD-180269</mixed-citation><mixed-citation xml:lang="en">Renard D, Tatu L, Collombier L, Wacongne A, Ayrignac X, Charif M, et al. Cerebral Amyloid Angiopathy and Cerebral Amyloid Angiopathy-Related Inflammation: Comparison of Hemorrhagic and DWI MRI Features. J Alzheimers Dis. 2018;64(4):1113–1121. doi: 10.3233/JAD-180269</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Auriel E, Charidimou A, Gurol ME, Ni J, Van Etten ES, Martinez-Ramirez S, et al. . Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy–Related Inflammation. JAMA Neurol. 2016 Feb;73(2):197–202. doi: 10.1001/jamaneurol.2015.4078</mixed-citation><mixed-citation xml:lang="en">Auriel E, Charidimou A, Gurol ME, Ni J, Van Etten ES, Martinez-Ramirez S, et al. . Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy–Related Inflammation.  JAMA  Neurol.  2016  Feb;73(2):197–202.  doi: 10.1001/jamaneurol.2015.4078</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kirshner HS, Bradshaw M. The Inflammatory Form of Cerebral Amyloid Angiopathy or BCerebral Amyloid Angiopathy–Related Inflammation (CAARI). Curr Neurol Neurosci Rep. 2015 Aug;15(8):54. doi: 10.1007/s11910-015-0572-y</mixed-citation><mixed-citation xml:lang="en">Kirshner HS, Bradshaw M. The Inflammatory Form of Cerebral Amyloid Angiopathy  or  BCerebral Amyloid Angiopathy–Related Inflammation (CAARI). Curr Neurol Neurosci Rep. 2015 Aug;15(8):54. doi: 10.1007/s11910-015-0572-y</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Charidimou A, Martinez-Ramirez S, Shoamanesh A et al. Cerebral amyloid angiopathy with and without hemorrhage: evidence for different disease phenotypes. Neurology. 2015;84:1206–12.</mixed-citation><mixed-citation xml:lang="en">Charidimou A, Martinez-Ramirez S, Shoamanesh A et al. Cerebral amyloid angiopathy with and without hemorrhage: evidence for different disease phenotypes. Neurology. 2015;84:1206–12.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">JH, Yu JT, Tan L. The role of cholesterol metabolism in Alzheimer’s disease. SunMol Neurobiol. 2015;51(3):947–65. doi: 10.1007/s12035-014-8749-y.</mixed-citation><mixed-citation xml:lang="en">JH, Yu JT, Tan L. The role of cholesterol metabolism in Alzheimer’s disease. SunMol Neurobiol. 2015;51(3):947–65. doi: 10.1007/s12035-014-8749-y.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pezzini A, Grassi M, Iacoviello L, et al. Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy) Investigators. Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on cerebral haemorrhage in Italy (MUCH-Italy). J Neurol Neurosurg Psychiatry. 2016;87:924–9.10. 1136/jnnp-2015-312736</mixed-citation><mixed-citation xml:lang="en">Pezzini A, Grassi M, Iacoviello L, et al. Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy) Investigators. Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on cerebral haemorrhage in Italy (MUCH-Italy). J Neurol Neurosurg  Psychiatry.  2016;87:924–9.10. 1136/jnnp-2015-312736</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering — are they clinically relevant? Eur Heart J. 2003;24:225–48.</mixed-citation><mixed-citation xml:lang="en">Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid  lowering  —  are  they  clinically  relevant?  Eur  Heart  J. 2003;24:225–48.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chan DK, O’Rourke F, Shen Q, Mak JC, Hung WT. Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurol Scand. 2011;124:188–195.</mixed-citation><mixed-citation xml:lang="en">Chan DK, O’Rourke F, Shen Q, Mak JC, Hung WT. Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurol Scand. 2011;124:188–195.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hackam DG, Hegele RA.Cholesterol Lowering and Prevention of Stroke An Overview. Stroke. 2019;50:00–00. DOI: 10.1161/STROKEAHA.118.023167</mixed-citation><mixed-citation xml:lang="en">Hackam DG, Hegele RA.Cholesterol Lowering and Prevention of Stroke An Overview. Stroke. 2019;50:00–00. DOI: 10.1161/STROKEAHA.118.023167</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Pezzini A, Del Zotto E, Volonghi I, et al. New insights into the pleiotropic effects of statins for stroke prevention. Mini Rev Med Chem. 2009;9:794–804.</mixed-citation><mixed-citation xml:lang="en">Pezzini A, Del Zotto E, Volonghi I, et al. New insights into the pleiotropic effects of statins for stroke prevention. Mini Rev Med Chem. 2009;9:794–804.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Bifulco M, Malfitano AM. Regulation of platelet function by statins. J Blood Disord. 2014;1:1–2.</mixed-citation><mixed-citation xml:lang="en">Bifulco M, Malfitano AM. Regulation of platelet function by statins. J Blood Disord. 2014;1:1–2.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Goldstein LB, Amarenco P, Szarek M, Callahan A III, Hennerici M, Sillesen H, et al; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70(24 pt 2):2364–2370. doi: 10.1212/01.wnl.0000296277.63350.77</mixed-citation><mixed-citation xml:lang="en">Goldstein LB, Amarenco P, Szarek M, Callahan A III, Hennerici M, Sillesen H, et al; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70(24 pt 2):2364–2370. doi: 10.1212/01.wnl.0000296277.63350.77</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Romero JR, Preis SR, Beiser A, et al. Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study. Stroke. 2014;45:1492–4. 10.1161/STROKEAHA.114.004130</mixed-citation><mixed-citation xml:lang="en">Romero JR, Preis SR, Beiser A, et al. Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study. Stroke. 2014;45:1492–4. 10.1161/STROKEAHA.114.004130</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Woo D, Deka R, Falcone GJ, et al. Apolipoprotein E, statins, and risk of intracerebral hemorrhage. Stroke. 2013;44:3013–7.</mixed-citation><mixed-citation xml:lang="en">Woo D, Deka R, Falcone GJ, et al. Apolipoprotein E, statins, and risk of intracerebral hemorrhage. Stroke. 2013;44:3013–7.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Martí-Fàbregas J, Medrano-Martorell S, Merino E et al. Statins do not increase Markers of Cerebral Angiopathies in patients with Cardioembolic Stroke. Sci Rep. 2018Jan 24;8(1):1492. doi: 10.1038/s41598-018-20055-3.</mixed-citation><mixed-citation xml:lang="en">Martí-Fàbregas J, Medrano-Martorell S, Merino E et al. Statins do not increase Markers of Cerebral Angiopathies in patients with Cardioembolic Stroke. Sci Rep. 2018Jan 24;8(1):1492. doi: 10.1038/s41598-018-20055-3.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ziff OJ, Banerjee G, Ambler G, Werring DJ. Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2019Jan;90(1):75–83. doi: 10.1136/jnnp-2018-318483</mixed-citation><mixed-citation xml:lang="en">Ziff OJ, Banerjee G, Ambler G, Werring DJ. Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review  and  meta-analysis.  J  Neurol  Neurosurg  Psychiatry. 2019Jan;90(1):75–83. doi: 10.1136/jnnp-2018-318483</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Phuah CL, Raffeld MR, Ayres AM, Viswanathan A, Greenberg SM, Biffi A, et al. Subacute decline in serum lipids precedes the occurrence of primary intracerebral hemorrhage. Neurology. 2016;86:2034–2041. doi: 10.1212/WNL.0000000000002716</mixed-citation><mixed-citation xml:lang="en">Phuah CL, Raffeld MR, Ayres AM, Viswanathan A, Greenberg SM, Biffi A, et al. Subacute decline in serum lipids precedes the occurrence of primary intracerebral hemorrhage. Neurology. 2016;86:2034–2041. doi: 10.1212/WNL.0000000000002716</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Lin HW, Ho YF, Lin FJ. Statin use associated with lower risk of epilepsy after intracranial haemorrhage: A population-based cohort study. Br J Clin Pharmacol. 2018Sep;84(9):1970–1979. doi: 10.1111/bcp.13626. Epub 2018 Jun 15.</mixed-citation><mixed-citation xml:lang="en">Lin HW, Ho YF, Lin FJ. Statin use associated with lower risk of epilepsy after intracranial haemorrhage: A population-based cohort study. Br J Clin Pharmacol. 2018Sep;84(9):1970–1979. doi: 10.1111/bcp.13626. Epub 2018 Jun 15.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Endres M, Nolte CH, Scheitz JF.Statin Treatment in Patients With Intracerebral Hemorrhage. Stroke. 2018 Jan;49(1):240–246. doi: 10.1161/STROKEAHA.117.019322</mixed-citation><mixed-citation xml:lang="en">Endres M, Nolte CH, Scheitz JF.Statin Treatment in Patients With Intracerebral Hemorrhage. Stroke. 2018 Jan;49(1):240–246. doi: 10.1161/STROKEAHA.117.019322</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722. doi: 10.1056/NEJMoa1615664</mixed-citation><mixed-citation xml:lang="en">Sabatine   MS,   Giugliano   RP,   Keech   AC,   Honarpour   N, Wiviott SD, Murphy SA, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with  cardiovascular  disease.  N  Engl  J  Med.  2017;376:1713–1722. doi: 10.1056/NEJMoa1615664</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Charidimou A, Boulouis G, Xiong L. et al. Cortical superficial siderosis and first-ever cerebral hemorrhage in cerebral amyloid angiopathy. Neurology. 2017 Apr 25;88(17):1607–1614. doi: 10.1212/WNL.0000000000003866.</mixed-citation><mixed-citation xml:lang="en">Charidimou A, Boulouis G, Xiong L. et al. Cortical superficial siderosis and first-ever cerebral hemorrhage in cerebral amyloid angiopathy.  Neurology.  2017  Apr  25;88(17):1607–1614.  doi: 10.1212/WNL.0000000000003866.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Charidimou A, Zonneveld HI, Shams S, Kantarci K, et al. APOE and cortical superficial siderosis in CAA: Meta-analysis and potential mechanisms. Neurology. 2019Jul;23;93(4):e358–e371. doi: 10.1212/WNL.0000000000007818.</mixed-citation><mixed-citation xml:lang="en">Charidimou A, Zonneveld HI, Shams S, Kantarci K, et al. APOE and  cortical  superficial siderosis  in  CAA:  Meta-analysis  and potential mechanisms. Neurology. 2019Jul;23;93(4):e358–e371. doi: 10.1212/WNL.0000000000007818.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Charidimou A, Linn J, Vernooij MW et al. Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. Brain. 2015;138(Pt 8):2126–39.</mixed-citation><mixed-citation xml:lang="en">Charidimou A, Linn J, Vernooij MW et al. Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. Brain. 2015;138(Pt 8):2126–39.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Linn J, Halpin A, Demaerel P et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010; 74:1346-50.</mixed-citation><mixed-citation xml:lang="en">Linn J, Halpin A, Demaerel P et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010; 74:1346-50.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Khurram A, Kleinig T, Leyden J. Clinical associations and causes of convexity subarachnoid hemorrhage. Stroke. 2014;45:1151–3.</mixed-citation><mixed-citation xml:lang="en">Khurram A, Kleinig T, Leyden J. Clinical associations and causes of convexity subarachnoid hemorrhage. Stroke. 2014;45:1151–3.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Charidimou A, Peeters AP, Jager R et al. Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy. Neurology. 2013;81:1666–73.</mixed-citation><mixed-citation xml:lang="en">Charidimou A, Peeters AP, Jager R et al. Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy. Neurology. 2013;81:1666–73.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Charidimou A, Boulouis G, Xiong L, Pasi M, Roongpiboonsopit D, Ayres A, Schwab KM, Rosand J, Gurol ME, Viswanathan A, Greenberg SM. Cortical Superficial Siderosis Evolution. Stroke. 2019Apr;50(4):954–962. doi: 10.1161/STROKEAHA.118.023368</mixed-citation><mixed-citation xml:lang="en">Charidimou  A,  Boulouis  G,  Xiong  L,  Pasi  M,  Roongpiboonsopit D, Ayres A, Schwab KM, Rosand J, Gurol ME, Viswanathan  A,  Greenberg  SM.  Cortical  Superficial  Siderosis Evolution. Stroke. 2019Apr;50(4):954–962. doi: 10.1161/STROKEAHA.118.023368</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Wollenweber F, Opherk C, Zedde M, Catak C, Malik R, Duering M et al. Prognostic relevance of cortical superficial siderosis in cerebral amyloid angiopathy. Neurology. 2019Feb;19;92(8):e792–e801. doi: 10.1212/WNL.0000000000006956</mixed-citation><mixed-citation xml:lang="en">Wollenweber F, Opherk C, Zedde M, Catak C, Malik R, Duering M et al. Prognostic relevance of cortical superficial siderosis in cerebral amyloid angiopathy. Neurology. 2019Feb;19;92(8):e792–e801. doi: 10.1212/WNL.0000000000006956</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Shahi Salman R, Dennis MS. Antiplatelet therapy may be continued after intracerebral hemorrhage. Stroke. 2014;45:3149–50.</mixed-citation><mixed-citation xml:lang="en">Al-Shahi Salman R, Dennis MS. Antiplatelet therapy may be continued after intracerebral hemorrhage. Stroke. 2014;45:3149–50.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Falcone GJ, Rosand J. Aspirin should be discontinued after lobar intracerebral hemorrhage. Stroke. 2014;45:3151–2.</mixed-citation><mixed-citation xml:lang="en">Falcone GJ, Rosand J. Aspirin should be discontinued after lobar intracerebral hemorrhage. Stroke. 2014;45:3151–2.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Biffi A, Halpin A, Towfighi A, Gilson A, Busl K, Rost N, Smith EE, Greenberg MS, Rosand J, Viswanathan A. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology. 2010Aug;24;75(8):693–8. doi: 10.1212/WNL.0b013e3181eee40f</mixed-citation><mixed-citation xml:lang="en">Biffi A,  Halpin A,  Towfighi A,  Gilson A,  Busl  K,  Rost  N, Smith EE, Greenberg MS, Rosand J, Viswanathan A. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology. 2010Aug;24;75(8):693–8. doi: 10.1212/WNL.0b013e3181eee40f</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">RESTARTCollaboration.Effectsofantiplatelet therapyafterstroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet. 2019Jun;29;393(10191):2613–2623. doi: 10.1016/S0140-6736(19)30840</mixed-citation><mixed-citation xml:lang="en">RESTARTCollaboration.Effectsofantiplatelet therapyafterstroke due to intracerebral haemorrhage (RESTART): a randomised, open-label  trial.  Lancet.  2019Jun;29;393(10191):2613–2623. doi: 10.1016/S0140-6736(19)30840</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurol. 2019Jul;18(7):643–652. doi: 10.1016/S1474-4422(19)30184-X</mixed-citation><mixed-citation xml:lang="en">RESTART Collaboration. Effects of antiplatelet therapy on stroke risk  by  brain  imaging  features  of  intracerebral  haemorrhage and  cerebral  small  vessel  diseases:  subgroup  analyses  of the  RESTART  randomised,  open-label  trial.  Lancet  Neurol. 2019Jul;18(7):643–652. doi: 10.1016/S1474-4422(19)30184-X</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson D, Ambler G et al. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol. 2019Jul;18(7):653–665. doi: 10.1016/S1474-4422(19)30197-8</mixed-citation><mixed-citation xml:lang="en">Wilson D, Ambler G et al. Cerebral microbleeds and stroke risk  after  ischaemic  stroke  or  transient  ischaemic  attack:  a pooled analysis of individual patient data from cohort studies. Lancet  Neurol.  2019Jul;18(7):653–665.  doi: 10.1016/S1474-4422(19)30197-8</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Janaway BM, Simpson JE, Hoggard N, et al, and the MRC Cognitive Function and Ageing Neuropathology Study. Brain haemosiderin in older people: pathological evidence for an ischaemic origin of magnetic resonance imaging (MRI) microbleeds. Neuropathol Appl Neurobiol. 2014;40:258–69.</mixed-citation><mixed-citation xml:lang="en">Janaway BM, Simpson JE, Hoggard N, et al, and the MRC Cognitive Function and Ageing Neuropathology Study. Brain haemosiderin   in   older   people:   pathological   evidence   for an ischaemic origin of magnetic resonance imaging (MRI) microbleeds. Neuropathol Appl Neurobiol. 2014;40:258–69.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Grutzendler J, Murikinati S, Hiner B, et al. Angiophagy prevents early embolus washout but recanalizes microvessels through embolus extravasation. Sci Transl Med. 2014;6:226ra31.</mixed-citation><mixed-citation xml:lang="en">Grutzendler J, Murikinati S, Hiner B, et al. Angiophagy prevents early embolus washout but recanalizes microvessels through embolus extravasation. Sci Transl Med. 2014;6:226ra31.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Ito AO, Shindo A, Ii Y, et al. Small cortical infarcts transformed to lobar cerebral microbleeds: A Case Series. J Stroke Cerebrovasc Dis. 2019;28:e30–32.</mixed-citation><mixed-citation xml:lang="en">Ito AO, Shindo A, Ii Y, et al. Small cortical infarcts transformed to lobar cerebral microbleeds: A Case Series. J Stroke Cerebrovasc Dis. 2019;28:e30–32.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019Jul;18(7):684–696. doi: 10.1016/S1474-4422(19)30079-1</mixed-citation><mixed-citation xml:lang="en">Wardlaw  JM,  Smith  C,  Dichgans  M.  Small  vessel  disease: mechanisms    and    clinical    implications.    Lancet    Neurol. 2019Jul;18(7):684–696. doi: 10.1016/S1474-4422(19)30079-1</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Liu W, Liu R, Sun W, Peng Q, Zhang W, Xu E, et al. CASISP Study Group. Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions. Stroke. 2012Nov;43(11):2916–22. doi: 10.1161/STROKEAHA.112.658369</mixed-citation><mixed-citation xml:lang="en">Liu W, Liu R, Sun W, Peng Q, Zhang W, Xu E, et al. CASISP Study Group. Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions. Stroke. 2012Nov;43(11):2916–22. doi: 10.1161/STROKEAHA.112.658369</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage. Biffi A, Anderson CD, Battey TW, Ayres AM, Greenberg SM, Viswanathan A, Rosand J. JAMA. 2015Sep;1;314(9):904–12. doi: 10.1001/jama.2015.10082</mixed-citation><mixed-citation xml:lang="en">Association  Between  Blood  Pressure  Control  and  Risk  of Recurrent Intracerebral Hemorrhage. Biffi A, Anderson CD, Battey  TW,  Ayres  AM,  Greenberg  SM,  Viswanathan  A, Rosand J. JAMA. 2015Sep;1;314(9):904–12. doi: 10.1001/jama.2015.10082</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Arima H, Tzourio C, Anderson C, Woodward M, Bousser MG, MacMahon S, et al. PROGRESS Collaborative Group. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke. 2010Feb;41(2):394–6. doi: 10.1161/STROKEAHA.109.563932</mixed-citation><mixed-citation xml:lang="en">Arima H, Tzourio C, Anderson C, Woodward M, Bousser MG, MacMahon   S,   et   al.   PROGRESS   Collaborative   Group. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke. 2010Feb;41(2):394–6. doi: 10.1161/STROKEAHA.109.563932</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
